Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Global, Phase 3, Multicenter, Open-Label Study to Assess the Long-Term Safety and Tolerability of NBI-1117568 in Adults With Schizophrenia

NCT07114874 is registered in ClinicalTrials.gov with Neurocrine Biosciences as lead sponsor.

NCT NCT07114874
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07114874 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Global, Phase 3, Multicenter, Open-Label Study to Assess the Long-Term Safety and Tolerability of NBI-1117568 in Adults With Schizophrenia
Lead sponsor
Neurocrine Biosciences
Phase
Phase 3
Overall status
Recruiting
Start date
July 11, 2025
Completion date
December 31, 2031
Enrollment
600 (estimated)
Sites
61

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia